Roberts Wealth Advisors LLC Buys 755 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Roberts Wealth Advisors LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 19,252 shares of the medical equipment provider’s stock after purchasing an additional 755 shares during the period. Roberts Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $1,756,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZBH. Garde Capital Inc. purchased a new stake in Zimmer Biomet during the 1st quarter valued at $29,000. Washington Trust Advisors Inc. purchased a new position in shares of Zimmer Biomet in the first quarter valued at about $30,000. Columbia River Financial Group LLC bought a new position in shares of Zimmer Biomet during the first quarter valued at about $30,000. Accent Capital Management LLC purchased a new stake in shares of Zimmer Biomet during the first quarter worth about $35,000. Finally, Cullen Frost Bankers Inc. grew its stake in shares of Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 305 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 1.9%

NYSE ZBH opened at $98.88 on Tuesday. The firm has a market capitalization of $19.59 billion, a PE ratio of 24.06, a P/E/G ratio of 2.32 and a beta of 0.67. The stock’s 50 day moving average is $100.93 and its 200 day moving average is $98.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have commented on the company. Stifel Nicolaus upped their price target on Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Redburn Partners set a $130.00 target price on Zimmer Biomet in a report on Thursday, September 18th. Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target on the stock. Finally, Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $112.44.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.